WO2002097056A3 - Method for generating replication defective viral vectors that are helper free - Google Patents
Method for generating replication defective viral vectors that are helper free Download PDFInfo
- Publication number
- WO2002097056A3 WO2002097056A3 PCT/US2002/017324 US0217324W WO02097056A3 WO 2002097056 A3 WO2002097056 A3 WO 2002097056A3 US 0217324 W US0217324 W US 0217324W WO 02097056 A3 WO02097056 A3 WO 02097056A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- viral vectors
- defective viral
- replication defective
- vectors
- generating replication
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14161—Methods of inactivation or attenuation
- C12N2750/14162—Methods of inactivation or attenuation by genetic engineering
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02734626A EP1402023A4 (en) | 2001-05-31 | 2002-05-31 | Method for generating replication defective viral vectors that are helper free |
AU2002305778A AU2002305778A1 (en) | 2001-05-31 | 2002-05-31 | Method for generating replication defective viral vectors that are helper free |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29479701P | 2001-05-31 | 2001-05-31 | |
US60/294,797 | 2001-05-31 | ||
US60/313,007 | 2001-08-07 | ||
US31300701P | 2001-08-17 | 2001-08-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002097056A2 WO2002097056A2 (en) | 2002-12-05 |
WO2002097056A3 true WO2002097056A3 (en) | 2003-11-13 |
Family
ID=26968754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/017324 WO2002097056A2 (en) | 2001-05-31 | 2002-05-31 | Method for generating replication defective viral vectors that are helper free |
Country Status (4)
Country | Link |
---|---|
US (2) | US8067156B2 (en) |
EP (1) | EP1402023A4 (en) |
AU (1) | AU2002305778A1 (en) |
WO (1) | WO2002097056A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8642341B2 (en) * | 2007-11-02 | 2014-02-04 | Cornell University | Materials and methods for gene mediated therapy of psychiatric disorders |
EP3105311A1 (en) | 2014-02-10 | 2016-12-21 | Univercells NV | System, apparatus and method for biomolecules production |
EP3294309A4 (en) | 2015-05-14 | 2019-01-16 | St. Jude Children's Research Hospital, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
WO2017066579A1 (en) * | 2015-10-14 | 2017-04-20 | Audentes Therapeutics, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
CN112041437A (en) | 2018-02-19 | 2020-12-04 | 同源药物公司 | Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof |
WO2020081415A1 (en) | 2018-10-15 | 2020-04-23 | Regenxbio Inc. | Method for measuring the infectivity of replication defective viral vectors and viruses |
US20220136004A1 (en) * | 2019-01-11 | 2022-05-05 | Chan Zuckerberg Biohub, Inc. | Targeted In Vivo Genome Modification |
KR20220031000A (en) * | 2019-07-03 | 2022-03-11 | 각꼬호우징 닛뽄 이까다이가꾸 | Method for preparing nucleic acid-encapsulated AAV hollow particles |
CN115197967B (en) * | 2021-04-08 | 2023-09-15 | 广州派真生物技术有限公司 | Helper plasmid for preparing recombinant adeno-associated virus and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009239A1 (en) * | 1991-11-08 | 1993-05-13 | Research Corporation Technologies, Inc. | Adeno-associated virus-2 basal vectors |
WO1994013788A1 (en) * | 1992-12-04 | 1994-06-23 | University Of Pittsburgh | Recombinant viral vector system |
US5869305A (en) * | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
WO2001025465A1 (en) * | 1999-10-07 | 2001-04-12 | University Of Iowa Research Foundation | Adeno-associated viruses and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6261834B1 (en) * | 1991-11-08 | 2001-07-17 | Research Corporation Technologies, Inc. | Vector for gene therapy |
US5658724A (en) * | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
US6686200B1 (en) * | 1993-08-31 | 2004-02-03 | Uab Research Foundation | Methods and compositions for the large scale production of recombinant adeno-associated virus |
WO1998009524A1 (en) * | 1996-09-06 | 1998-03-12 | Chiron Corporation | Methods and compositions for liver specific delivery of therapeutic molecules using recombinant aav vectors |
US6221646B1 (en) * | 1997-07-31 | 2001-04-24 | Chiron Corporation | Materials and methods for simplified AAV production |
US6436392B1 (en) * | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
WO2000028004A1 (en) * | 1998-11-10 | 2000-05-18 | The University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
US6893865B1 (en) * | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
-
2002
- 2002-05-31 EP EP02734626A patent/EP1402023A4/en not_active Withdrawn
- 2002-05-31 AU AU2002305778A patent/AU2002305778A1/en not_active Abandoned
- 2002-05-31 US US10/159,968 patent/US8067156B2/en not_active Expired - Fee Related
- 2002-05-31 WO PCT/US2002/017324 patent/WO2002097056A2/en not_active Application Discontinuation
-
2011
- 2011-11-22 US US13/302,057 patent/US20120117674A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009239A1 (en) * | 1991-11-08 | 1993-05-13 | Research Corporation Technologies, Inc. | Adeno-associated virus-2 basal vectors |
WO1994013788A1 (en) * | 1992-12-04 | 1994-06-23 | University Of Pittsburgh | Recombinant viral vector system |
US5869305A (en) * | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
WO2001025465A1 (en) * | 1999-10-07 | 2001-04-12 | University Of Iowa Research Foundation | Adeno-associated viruses and uses thereof |
Non-Patent Citations (1)
Title |
---|
LUSBY E. ET AL.: "Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA", J. VIROL., vol. 34, no. 2, May 1980 (1980-05-01), pages 402 - 409, XP002968335 * |
Also Published As
Publication number | Publication date |
---|---|
EP1402023A2 (en) | 2004-03-31 |
US20120117674A1 (en) | 2012-05-10 |
EP1402023A4 (en) | 2005-06-15 |
US20030152914A1 (en) | 2003-08-14 |
US8067156B2 (en) | 2011-11-29 |
WO2002097056A2 (en) | 2002-12-05 |
AU2002305778A1 (en) | 2002-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1381280A4 (en) | Viral vectors and their use in therapeutic methods | |
IL176407A0 (en) | Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases | |
NO20041882L (en) | Methods for the treatment of ocular neovascular diseases. | |
EP1545558A4 (en) | 1, 3, 5-triazines for treatment of viral diseases | |
IL157946A0 (en) | Combination therapy | |
HUP0303917A2 (en) | Combinations of sterol absorption inhibitir(s) with blood modifier(s) and their use for treating vascular conditions | |
ZA200305126B (en) | Methods of administering epothilone analogs for the treatment of cancer. | |
WO2003039462A3 (en) | B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies | |
NO20041277L (en) | Pharmaceutical preparations for the treatment of asthma. | |
AU2001235006A1 (en) | Prophylactic and therapeutic monoclonal antibodies | |
MXPA03009772A (en) | Methods and compositions for treating oral and eosophageal lesions. | |
CY1112957T1 (en) | NON-NEUROTOTOXIC FACTORS, WHICH INCLUDE PLASMINOGENE FOR TREATMENT INTRODUCTION | |
WO2002097056A3 (en) | Method for generating replication defective viral vectors that are helper free | |
PT1409692E (en) | Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine | |
AU2003271021A1 (en) | Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof | |
PT1434588E (en) | 2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino alkyl -acid derivatives for the treatment of pain | |
PL367627A1 (en) | 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof | |
HUP0401188A3 (en) | Hyperbranched amylopectin for use in methods for surgical or therapeutic treatment of mammals or in diagnostic methods, especially for use as a plasma volume expander | |
MXPA03006412A (en) | Methods of administering epothilone analogs for the treatment of cancer. | |
WO2002081627A3 (en) | Methods of screening and using inhibitors of angiogenesis | |
NO20042586L (en) | Treatment Progress Mate | |
AU2002340728A1 (en) | Tt virus sequences in human tumoral tissue, agent for the detection thereof and tumoral therapy | |
PT1474415E (en) | 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, the use thereof for producing drugs used in the treatment of immunological diseases | |
ZA200300675B (en) | Pharmaceutical preparation of the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma. | |
IL161004A0 (en) | Ophthalmologic treatment methods using selective inos inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002734626 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002734626 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002734626 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |